Stockreport

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medic...

Nuvation Bio Inc. Class A  (NUVB) 
PDF Additional filings are planned for the U.K., Canada and other regions included in Eisai's licensed territories Taletrectinib is already approved in the U.S., China an [Read more]